Detalhe da pesquisa
1.
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.
Dermatol Ther (Heidelb)
; 12(9): 2063-2075, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917057